Calliditas Q2: A solid US launch - Redeye

Calliditas recorded Q2 sales are SEK 64m in Q2 compared with SEK 0m in Q2 2021, and Tarpeyo product sales accounted for SEK 64m. Calliditas can point to a “strong interest” in Tarpeyo, with the number of unique Rx growing from 111 to 314 and enrollments increasing from 134 to 315. Calliditas European partner STADA can now be expected to launch Tarpeyo/Kinpeygo in Europe during H2 2022.

Länk till analysen i sin helhet: https://www.redeye.se/research/852054/calliditas-q2-2022-a-solid-us-launch?utm_source=finwire&utm_medium=RSS